Oxford Nanopore Technologies said Norway’s MATRIX program has rolled out a rapid nanopore-sequencing approach for central nervous system (CNS) tumor classification across the country’s public healthcare system. The deployment is being integrated into Norway’s National Infrastructure for Precision Diagnostics (InPreD), aiming to provide rapid insights and real-time decision-making for CNS tumor patients. The rollout is built on a “successful clinical evaluation” from a Phase 1 assessment of 50 CNS tumor samples using an assay developed by Oslo University Hospital, with Oxford Nanopore reporting strong agreement versus established diagnostic methods. For Phase 2, the initial deployment sites include Oslo University Hospital, Haukeland University Hospital, and St. Olavs Hospital, supported by regional health authorities and the Norwegian Cancer Society. The program includes training, laboratory information system integration, logistics, bioinformatics validation, and diagnostic pathway support. Oxford Nanopore also said it will expand the collaboration beyond classification to include variant detection, copy number variation benchmarking, single-cell transcriptomics, and genome-wide methylation, while Oslo University Hospital plans to submit documentation aligned with the EU In Vitro Diagnostic Regulation (IVDR) later this year.